PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS

• Guillermo Garcia-Manero,
• Rayna K. Matsuno,
• Ali Mcbride,
• Adeola Y Makinde,
• Thomas D. Brown,
• Danny Idryo,
• Ronda Broome,
• Autumn Herriman,
• Kristiana Wilkinson,
• Sheetal Walters,
• Andrew Schrag,
• Hina Mohammed,
• Monika A. Izano,
• Sudipto Mukherjee

Affiliations

Guillermo Garcia-Manero

1 MD Anderson Cancer Center, Houston, TX, United States

Rayna K. Matsuno

2 Syapse, San Francisco, CA, United States

Ali Mcbride

3 Bristol Myers Squibb, Princeton, NJ, United States

Adeola Y Makinde

3 Bristol Myers Squibb, Princeton, NJ, United States

Thomas D. Brown

2 Syapse, San Francisco, CA, United States

Danny Idryo

2 Syapse, San Francisco, CA, United States

Ronda Broome

2 Syapse, San Francisco, CA, United States

Autumn Herriman

2 Syapse, San Francisco, CA, United States

Kristiana Wilkinson

2 Syapse, San Francisco, CA, United States

Sheetal Walters

2 Syapse, San Francisco, CA, United States

Andrew Schrag

2 Syapse, San Francisco, CA, United States

Hina Mohammed

2 Syapse, San Francisco, CA, United States

Monika A. Izano

2 Syapse, San Francisco, CA, United States

Sudipto Mukherjee

4 Cleveland Clinic, Cleveland, OH, United States